- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older.
This study looks at a new flu jab for people aged 50 and over. It compares how well this new high-dose jab works and its safety, against two other existing flu jabs. The aim is to find out if the new jab offers better protection.
For: Healthy individuals or individuals with stable comorbidities which increase their risk of complications from influenza infection.Denmark · Estonia · Germany - AuthorisedTherapeutic use (Phase IV)
Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.
This study looks at how well RSV vaccines work in people with inflammatory rheumatic diseases. We want to see if their anti-rheumatic medicines affect how their body responds to the vaccine and creates protection against the RSV virus.
For: Inflammatory rheumatic diseaseSweden - AuthorisedTherapeutic confirmatory (Phase III)
Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial
Researchers are looking into new ways to protect babies from a common chest infection called RSV. This study is testing special medicines designed to prevent RSV in infants. It aims to see how well these work and keep babies healthy.
For: Respiratory Syncytial Virus (RSV)Belgium · Netherlands